[Expression of high-mobility group box 1 in neonates with sepsis].
Journal
Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
ISSN: 1008-8830
Titre abrégé: Zhongguo Dang Dai Er Ke Za Zhi
Pays: China
ID NLM: 100909956
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
entrez:
21
2
2019
pubmed:
21
2
2019
medline:
10
4
2019
Statut:
ppublish
Résumé
To study the expression of high-mobility group box 1 (HMGB1) in neonates with sepsis and its role in the pathogenesis of neonatal sepsis. A total of 62 neonates with sepsis were enrolled as the sepsis group, 66 neonates with local infection were enrolled as the local infection group, and 70 healthy neonates were enrolled as the healthy control group. Serum levels of interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-17 (IL-17), interleukin-23 (IL-23), C-reactive protein (CRP) and procalcitonin (PCT) were measured. The mRNA expression of HMGB1, Toll-like receptor 4 (TLR4) and nuclear factor-kappa B (NF-κB) and the protein expression of TLR4 and NF-κB in peripheral blood mononuclear cells (PBMCs) were also measured. PBMCs from healthy neonates were divided into 4 groups: control, HMGB1 treatment, HMGB1+TAK-242 (a TLR4 inhibitor) treatment and HMGB1+PDTC (an NF-κB inhibitor) treatment, and the mRNA expression of TLR4, NF-κB and IL-8 and the protein expression of TLR4 and NF-κB were measured. PBMCs from healthy neonates were divided into another 3 groups: control, LPS treatment and LPS+glycyrrhizin (an HMGB1 inhibitor) treatment, and the mRNA expression of HMGB1, TLR4, NF-κB and IL-8 and the protein expression of TLR4 and NF-κB were measured. Compared with the local infection and healthy control groups, the sepsis group had significantly higher serum levels of IL-6, IL-8, IL-17, IL-23, CRP and PCT (P<0.05), as well as significantly higher mRNA expression of HMGB1, TLR4 and NF-κB and protein expression of TLR4 and NF-κB in PBMCs (P<0.05). HMGB1 significantly induced the mRNA and protein expression of TLR4 and NF-κB in PBMCs (P<0.05). TAK-242 inhibited the mRNA and protein expression of TLR4 and NF-κB and mRNA expression of IL-8 (P<0.05). PDTC inhibited the mRNA and protein expression of NF-κB and the mRNA expression of IL-8 (P<0.05). LPS significantly induced the mRNA expression of HMGB1 and the mRNA and protein expression of TLR4 and NF-κB and then stimulated the mRNA expression of IL-8 (P<0.05). Glycyrrhizin inhibited the mRNA expression of HMGB1 and the mRNA and protein expression of TLR4 and NF-κB and then reduced the mRNA expression of IL-8 (P<0.05). HMGB1 plays an important role in the pathogenesis of neonatal sepsis by activating the TLR4/NF-κB signaling pathway and inducing the secretion of inflammatory factors including IL-8. The HMGB1 blocker glycyrrhizin can inhibit activation of the TLR4/NF-κB signaling pathway and the secretion of inflammatory factors.
Identifiants
pubmed: 30782274
pii: 10.7499/j.issn.1008-8830.2019.02.005
pmc: PMC7389828
Substances chimiques
HMGB1 Protein
0
HMGB1 protein, human
0
NF-kappa B
0
Types de publication
Journal Article
Langues
chi
Sous-ensembles de citation
IM
Pagination
131-138Références
Toxicol Appl Pharmacol. 2017 Aug 15;329:202-211
pubmed: 28610995
Biochem Pharmacol. 2013 Aug 1;86(3):410-8
pubmed: 23707973
Am J Transl Res. 2017 Dec 15;9(12):5181-5196
pubmed: 29312476
Nat Med. 2004 Nov;10(11):1216-21
pubmed: 15502843
Invest Ophthalmol Vis Sci. 2016 Oct 1;57(13):5799-5809
pubmed: 27792814
Mol Med Rep. 2018 Feb;17(2):2915-2920
pubmed: 29257249
Inflammation. 2016 Oct;39(5):1718-28
pubmed: 27447821
Bull World Health Organ. 2015 Jan 1;93(1):19-28
pubmed: 25558104
Oncotarget. 2017 May 16;8(38):64534-64550
pubmed: 28969092
Clin Lab. 2016 Dec 1;62(12):2379-2385
pubmed: 28164547
Biosci Rep. 2016 Jan 07;36(1):e00300
pubmed: 26744383
Am J Transl Res. 2018 May 15;10(5):1273-1283
pubmed: 29887944
Am J Transl Res. 2016 Dec 15;8(12):5519-5531
pubmed: 28078023
Inflammation. 2016 Aug;39(4):1594-602
pubmed: 27363991
J Neuroinflammation. 2016 Sep 08;13(1):241
pubmed: 27609334
Int J Mol Med. 2016 Jan;37(1):99-107
pubmed: 26719855
Immunol Rev. 2017 Nov;280(1):74-82
pubmed: 29027228
Int J Mol Cell Med. 2017 Summer;6(3):148-155
pubmed: 29682486
Nature. 2002 Jul 11;418(6894):191-5
pubmed: 12110890